BRT Biotechnologies

BRT Biotechnologies is an early-stage biotechnology company that utilizes its proprietary BRiTeCycle platform to rapidly generate large, diverse libraries of macrocycles for drug discovery. The company’s approach is designed to synthesize high-quality molecules—including peptides—that bind to drug targets with high affinity and selectivity. By employing a tag-free and barcode-free synthetic process, the platform allows for ultra-high-throughput synthesis, which supports both target-based and phenotypic screening. This technology is specifically intended to address challenges in drug discovery by enabling faster iteration and hit-to-lead optimization, targeting molecules that were previously considered difficult to drug.

This technology is primarily utilized by partners and researchers looking to accelerate early-stage drug discovery efforts. By providing diverse lead compounds and rapid follow-up on promising hits, BRT Biotechnologies assists in making more informed decisions during the hit-to-lead process. Headquartered in Claremont, California, and founded in 2021, the company engages with the scientific community through posters and industry symposia, demonstrating its capabilities in macrocyclic peptide drug discovery and hit optimization. The platform’s ability to deliver refined analogs quickly is tailored to help drug hunters overcome barriers in identifying precision therapies for complex diseases.